Qualigen Therapeutics, Inc. (NASDAQ:QLGN) has a beta value of -0.7 and has seen 531,939 shares traded in the last trading session. The company, currently valued at $106.57 Million, closed the last trade at $4.73 per share which meant it lost -$0.01 on the day or -0.21% during that session. The QLGN stock price is -354.55% off its 52-week high price of $21.5 and 21.56% above the 52-week low of $3.71. If we look at the company’s 10-day average daily trading volume, we find that it stood at 936.33 Million shares traded. The 3-month trading volume is 1.76 Million shares.

The consensus among analysts is that Qualigen Therapeutics, Inc. (QLGN) is a Hold stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 1 have rated it as a Hold, with no one of them advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) trade information

Despite being -0.21% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Oct 13 when the QLGN stock price touched $5.08-6 or saw a rise of 6.89%. Year-to-date, Qualigen Therapeutics, Inc. shares have moved 12.02%, while the 5-day performance has seen it change -6.71%. Over the past 30 days, the shares of Qualigen Therapeutics, Inc. (NASDAQ:QLGN) have changed 0.85%. Short interest in the company has seen 1.35 Million shares shorted with days to cover at 0.77.

Wall Street analysts have a consensus price target for the stock at $175, which means that the shares’ value could jump 3599.79% from current levels. The projected low price target is $175 while the price target rests at a high of $175. In that case, then, we find that the current price level is +3599.79% off the targeted high while a plunge would see the stock lose 3599.79% from current levels.

Qualigen Therapeutics, Inc. (QLGN) estimates and forecasts

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +28% over the past 5 years. Earnings growth for 2020 is a modest +71.1%.

Qualigen Therapeutics, Inc. (NASDAQ:QLGN)’s Major holders

The other major institutional holder is Acadian Asset Management, with the holding of over 30Thousand shares as of June 29, 2020. The firm’s total holdings are worth over $119.09 Thousand and represent 0.14% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Extended Market Index Fund and USAA Mutual Fd Tr-Extended Market Index Fd. As of June 29, 2020, the former fund manager holds about 0.02% shares in the company for having 3643 shares of worth $14.46 Thousand while later fund manager owns 2.09 Thousand shares of worth $8.28 Thousand as of June 29, 2020, which makes it owner of about 0.01% of company’s outstanding stock.